StockNews.com assumed coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC – Get Rating) in a research note issued to investors on Monday morning. The firm issued a sell rating on the biotechnology company’s stock.
Shares of NASDAQ CYCC opened at $2.05 on Monday. Cyclacel Pharmaceuticals has a twelve month low of $1.96 and a twelve month high of $7.95. The stock’s 50 day moving average price is $3.19 and its 200-day moving average price is $3.88. The company has a market capitalization of $20.49 million, a PE ratio of -0.96 and a beta of 1.21.
Cyclacel Pharmaceuticals (NASDAQ:CYCC – Get Rating) last announced its earnings results on Monday, March 28th. The biotechnology company reported ($0.54) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.17. During the same period in the previous year, the company posted ($1.34) earnings per share. Research analysts expect that Cyclacel Pharmaceuticals will post -3.46 earnings per share for the current fiscal year.
About Cyclacel Pharmaceuticals (Get Rating)
Cyclacel Pharmaceuticals, Inc is a clinical stage biopharmaceutical company. It uses cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. The company builds a biopharmaceutical business, which is focused in hematology and oncology based on a pipeline of novel drug candidates.
- Get a free copy of the StockNews.com research report on Cyclacel Pharmaceuticals (CYCC)
- OrganiGram’s Turnaround Begins To Blossom
- Three Dividend Stocks With Growth Potential
- Exelon Stock Still Has Extraordinary Upside
- Ross Stores On The Verge Of Major Rally
- Greenbrier Companies Stock has Green in its Future
Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.